Loading...
OTCM
FSNUY
Market cap62bUSD
Dec 04, Last price  
13.95USD
1D
0.43%
1Q
0.79%
Jan 2017
-28.39%
Name

Fresenius SE & Co KGaA

Chart & Performance

D1W1MN
OTCM:FSNUY chart
P/E
14.32
P/S
0.31
EPS
0.84
Div Yield, %
Shrs. gr., 5y
0.21%
Rev. gr., 5y
-9.22%
Revenues
21.83b
-2.09%
7,889,000,00010,777,000,00011,358,000,00012,336,000,00014,164,000,00015,972,000,00016,522,000,00019,290,000,00020,331,000,00023,231,000,00027,626,000,00029,083,000,00033,886,000,00033,530,000,00035,409,000,00036,277,000,00037,520,000,00040,840,000,00022,299,000,00021,833,000,000
Net income
471m
P
222,000,000330,000,000410,000,000270,000,000991,000,0001,205,000,0001,328,000,000926,000,0001,011,000,0001,067,000,0001,358,000,0001,593,000,0001,814,000,0002,027,000,0001,883,000,0001,707,000,0001,818,000,0001,372,000,000-594,000,000471,000,000
CFO
2.45b
-45.09%
780,000,0001,052,000,0001,296,000,0001,074,000,0001,553,000,0001,911,000,0001,689,000,0002,438,000,0002,320,000,0002,585,000,0003,327,000,0003,574,000,0003,937,000,0003,742,000,0004,263,000,0006,549,000,0005,078,000,0004,198,000,0004,456,000,0002,447,000,000
Dividend
May 18, 20230.26719 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Fresenius SE & Co. KGaA, a health care company, provides products and services for dialysis, hospitals, and outpatient medical care. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, hemodialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of therapy and care ill patients. This segment offers IV drugs, including intravenously administered generic drugs for oncology, anesthetics, analgesics, anti-infectives, and critical care; parenteral and enteral nutrition products; infusion solutions and blood volume substitutes for infusion therapy; biosimilars, a biological medicine for autoimmune and oncology diseases; medical devices and disposal used to administer IV generic drugs, infusion therapies, and clinical nutrition products; and transfusion products for collection of blood components and corporeal therapies. The Fresenius Helios segment operates 90 hospitals, approximately 130 outpatient clinics, and 6 prevention centers in Germany; and 49 hospitals, 88 outpatient clinics, and approximately 300 risk prevention centers in Spain. This segment also provides services in the field of fertility treatments through 33 clinics and additional 39 sites across 10 countries on 3 continents. The Fresenius Vamed segment manages projects and offers services for hospitals and other health care facilities. This segment provides project development, planning, and turnkey construction services, as well as maintenance, technical management, and operational management services. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.
IPO date
Dec 18, 1986
Employees
315,233
Domiciled in
DE
Incorporated in
DE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT